AMARIN CORP PLC\UK Payments of Debt Restructuring Costs
AMARIN CORP PLC\UK (AMRN) reported Payments of Debt Restructuring Costs of $121.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtRestructuringCosts · last filed 2021-02-25
- AMARIN CORP PLC\UK payments of debt restructuring costs for the quarter ending 2016-12-31 was $2.00K.
- AMARIN CORP PLC\UK payments of debt restructuring costs for fiscal 2018 was $121.00K.
- AMARIN CORP PLC\UK payments of debt restructuring costs for fiscal 2016 was $680.00K.
| Period end | Payments of Debt Restructuring Costs 3 month | Payments of Debt Restructuring Costs 9 month | Payments of Debt Restructuring Costs 12 month |
|---|---|---|---|
| 2018-12-31 | $121.00K 10-K · filed 2021-02-25 | ||
| 2016-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $680.00K 10-K · filed 2019-02-27 | |
| 2016-09-30 | $678.00K 10-Q · filed 2017-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |